14.05.2013 • News

Aesica Enters Research Collaboration with University of Nottingham

Aesica, the global contract manufacturing organisation (CMO), announces a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis. This latest partnership is already the Aesica Innovation Board's (AIB) fourth with an academic institution in less than six months; having been established to help bridge the growing R&D gap by identifying early stage technologies for development into commercial applications.

Amide bond formation is fundamental in pharmaceutical manufacturing. A recent survey conducted by the Green Chemistry Institute Roundtable identified that amide bond formation was utilised in 84 % of a set of drug candidates. The partnership's aim is to revolutionize traditional amide formation techniques by generating alternative methods for amide bond formation, which will be more eco-friendly and chemically versatile. This innovative approach will be commercially available to Aesica customers in the next two to three months and already the company is actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.

This collaboration builds upon recently announced plans to establish a Centre of Excellence for Sustainable Chemistry, part-funded by an investment from the Higher Education Funding Council for England (HEFCE) UK Research Partnership Investment Fund.

 

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.